-- Jarden週二在一份報告中指出，西太平洋銀行（ASX：WBC）已「顯著」提升其成長和風險承受能力，以實現更大的資產負債表和更高的收入基礎，從而提高盈利。 截至3月份的三個月內，該銀行的總資本為985.4億澳元，高於去年同期的971.4億澳元。根據週二提交給澳洲證券交易所的文件，該行同期的CET1資本為569.4億澳元，高於2025年3月季度報告的550.1億澳元。 這家投資公司表示，西太平洋銀行旨在優化其內部技術系統的UNITE計畫是正確的舉措，但實施起來可能並不容易。預計該計劃成本更高、耗時更長，並可能導致資產減損。 該券商的分析師也警告稱，如果當前的中東衝突引發信貸週期，那麼加速成長和公司風險偏好的提高可能會適得其反。 Jarden 給予該公司「減持」評級，目標價為 32 澳元。
Related Articles
Asia
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
$HKG:2096
Asia
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
$HKG:1357
Asia
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.
$HKG:2158